Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Net Cash Flow (2016 - 2025)

Heron Therapeutics' Net Cash Flow history spans 14 years, with the latest figure at -$14.4 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 23740.98% year-over-year to -$14.4 million; the TTM value through Dec 2025 reached $2.8 million, up 198.96%, while the annual FY2025 figure was $2.8 million, 198.96% up from the prior year.
  • Net Cash Flow reached -$14.4 million in Q4 2025 per HRTX's latest filing, down from $26.6 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $131.4 million in Q2 2021 to a low of -$69.0 million in Q4 2021.
  • Average Net Cash Flow over 5 years is -$3.8 million, with a median of -$6.4 million recorded in 2023.
  • Peak YoY movement for Net Cash Flow: skyrocketed 1069.87% in 2023, then crashed 23740.98% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$69.0 million in 2021, then soared by 49.19% to -$35.1 million in 2022, then surged by 82.37% to -$6.2 million in 2023, then surged by 100.99% to $61000.0 in 2024, then plummeted by 23740.98% to -$14.4 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Net Cash Flow are -$14.4 million (Q4 2025), $26.6 million (Q3 2025), and -$2.8 million (Q2 2025).